176 related articles for article (PubMed ID: 34741961)
1. COVID 19 and the risk of gastro-intestinal perforation: A case series and literature review.
Bulte JP; Postma N; Beukema M; Inberg B; Stegeman AG; van der Hoeven H
J Crit Care; 2022 Feb; 67():100-103. PubMed ID: 34741961
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 infection and large intestinal perforation: A case series.
Masanam MK; Cheney SM; Sutton W; Keyloun JW; Fitzgibbons S
Int J Surg Case Rep; 2022 Sep; 98():107538. PubMed ID: 36027834
[TBL] [Abstract][Full Text] [Related]
4. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.
Gout T; Ostör AJ; Nisar MK
Clin Rheumatol; 2011 Nov; 30(11):1471-4. PubMed ID: 21833686
[TBL] [Abstract][Full Text] [Related]
5. Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment.
Vaxman I; Al Saleh AS; Kumar S; Nitin M; Dispenzieri A; Buadi F; Dingli D; Lacy M; Muchtar E; Hobbs M; Fonder A; Hwa L; Visram A; Kapoor P; Siddiqui M; Lust J; Kyle R; Rajkumar V; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Gertz MA
Cancer Med; 2020 Dec; 9(23):8895-8901. PubMed ID: 33022868
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
Vikse J; Henry BM
Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
[No Abstract] [Full Text] [Related]
7. Colonic perforation in patients with COVID-19 pneumonia - case reports.
Filová M; Adamová Z
Rozhl Chir; 2021; 100(7):353-356. PubMed ID: 34465112
[TBL] [Abstract][Full Text] [Related]
8. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
[TBL] [Abstract][Full Text] [Related]
9. Gastro-intestinal tract perforation in neonates.
Kuremu RT; Hadley GP; Wiersma R
East Afr Med J; 2003 Sep; 80(9):452-5. PubMed ID: 14640165
[TBL] [Abstract][Full Text] [Related]
10. Sigmoid colon perforation in a SARS-CoV-2 positive neonate: a uniqueness report and a brief review.
Jamali Z; Sinaei R; Estabragh ER; Ahangaran A
BMC Pediatr; 2022 Jun; 22(1):327. PubMed ID: 35659271
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal Perforation After Treatment With Tocilizumab : An Unexpected Consequence of COVID-19 Pandemic.
Rojo M; Cano-Valderrama O; Picazo S; Saez C; Gómez L; Sánchez C; Sanz-Ortega G; Torres AJ
Am Surg; 2020 Jun; 86(6):565-566. PubMed ID: 32683974
[No Abstract] [Full Text] [Related]
12. Tocilizumab-Associated Bowel Perforation in SARS-CoV-2 Infection.
Ranchal P; Yates E; Gupta R; Aronow WS
Am J Ther; 2022 Nov-Dec 01; 29(6):e699-e702. PubMed ID: 33021529
[No Abstract] [Full Text] [Related]
13. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal perforation secondary to COVID-19: Case reports and literature review.
Al Argan RJ; Alqatari SG; Al Said AH; Alsulaiman RM; Noor A; Al Sheekh LA; Al Beladi FH
Medicine (Baltimore); 2021 May; 100(19):e25771. PubMed ID: 34106608
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
17. Unpredictability of SARS-CoV-2: Pneumoperitoneum a rare complication.
Rehman HU; Javed A; Akhunzada HA; Tariq N; Abbassi N
J Pak Med Assoc; 2022 Oct; 72(10):2108-2111. PubMed ID: 36661009
[TBL] [Abstract][Full Text] [Related]
18. A Case of Abdominal Perforation in a COVID+ Patient Treated With Tocilizumab and Corticosteroids.
Chaudhry B; Alekseyev K; Didenko L; Chaudhry M
Clin Med Insights Case Rep; 2023; 16():11795476231173870. PubMed ID: 37342097
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal complications (gangrene or perforation) after corona virus disease 2019 - A series of ten patients.
Chaugale SB; Singhal V; Kapoor D; Singh A
Indian J Gastroenterol; 2022 Jun; 41(3):307-312. PubMed ID: 35471720
[TBL] [Abstract][Full Text] [Related]
20. Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.
Masotti L; Landini G; Panigada G; Grifoni E; Tarquini R; Cei F; Cimolato BMA; Vannucchi V; Di Pietro M; Piani F; Fortini A; Faraone A; Nenci G; Cipollini F; Blanc P; Lotti P; Di Natale M; Risaliti F; Aquilini D; Seravalle C; Bribani A; Farsi A; Micheletti I; Cioni E; Pelagalli G; Mattaliano C; Pinto G; Madonia EM; Sivieri I; Mannini M; Valoriani A; Brancati S; Rosselli M; Pavone E; Burla MC; Sergi A;
Int Immunopharmacol; 2022 Jun; 107():108709. PubMed ID: 35334359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
